

Index

- A1C values, 63
- absolute neutrophil count (ANC), 6, 7, 115
- baseline, 63
 - DARC genotype, 119
 - low baseline, addressing, 120–122
 - low, and treatment interruption, 131–134
 - monitoring guidelines, USA, 126
 - threshold, 116, 117
 - UK hematologic monitoring, 128
- ACHIEVE protocol, 217
- adherence. *See* nonadherence
- adolescents, 277, 279–285
- adverse effects of clozapine, 284
 - intellectually disabled, 290
 - plasma clozapine levels, 282
 - principles for clozapine use, 281
 - randomized double-blind studies, 279
- African descent, 6, 117, 118, 119, 280
- aggression, 27–31, 289
- agranulocytosis, 115, 116
- akathisia, 280, 281, 284
- alanine aminotransferase (ALT), 259, 260, 269, 270, 271
- alpha₁ antagonism, 99, 166, 247
- alpha-synuclein, 33
- amisulpride, 49, 184
- amphetamines, 163
- anemia, 259, 267–268
- general approach to, 265
 - incidence of, 259
- anticholinergics, 73
- approximate equivalents, 82
 - cholinergic rebound, 80, 81
 - constipation and, 144, 145
 - daily maximum limits, 82
 - equivalencies, 74, 145
 - sialorrhea and, 173, 178
- anticonvulsants, 193, 195, 198, 200
- antidepressants, tricyclic, 74, 144
- antihypertensives, 75
- antiparkinsonian medications, 145
- antipsychotics. *See also individual antipsychotics*
- augmenting clozapine, 48–49
 - consensus criteria for an adequate trial, 15
 - double-blind trials, 12
 - mortality studies, 20
 - plasma levels, 45
 - provision of appropriate, 83–86
 - real-world effectiveness studies, 17
 - tapering, 75
 - weight gain and, 210, 211
- antisocial personality disorders, 29
- aripiprazole, 49, 212
- OCD and, 253
 - sedation and, 162
- armodafinil, 163
- aromatic hydrocarbon receptor (AhR), 96
- aspartate aminotransferase (AST), 259, 260, 269, 270, 271
- aspiration pneumonia, 173

INDEX

- atenolol, 168
 atonic seizures, 194
 atropine, 173, 178, 179, 181
 Australia, clozapine registration, 66
- bacterial infections, 103, 105,
 106–108
 clozapine management during,
 107
 minimization of risk, 135
- bariatric surgery, 212
 baseline laboratory measures, 63
 baseline vital signs, 62
 baseline work-up, 62, 65
 baseline, low, ANC, 120–122
 Bazett formula, 48, 64, 65, 167
 benign ethnic neutropenia (BEN), 6,
 7, 66, 115, 118–119
 ANC threshold, 117
 definition of, 119
 diagnosis, 119
 hematologic monitoring, 116
 hematologic monitoring, UK,
 129
 hematologic monitoring, USA,
 127
- benzodiazepines, 73
 benztropine, 153
 cholinergic rebound, 81, 82
- BID dosing, 97
 binding profile, 98–102
 bioavailability, 72, 91, 93
 bipolar disorder, manic phase of, 32
 bisacodyl, 146
 body mass index (BMI), 63, 65,
 208
 botulinum toxin-A, 181, 182
 botulinum toxin-B, 173, 178,
 180–183
 breastfeeding, 277, 278, 295–296
- Brief Psychiatric Rating Scale
 (BPRS), 48, 49, 51
- Bristol Stool Form Scale, 143, 144,
 145
 bulk-forming laxatives, 147, 148
 bupropion, 218
- caffeine, 96
 Cal-DSH, 149, 150
 Canada, clozapine registration, 66
 carbachol, 99, 176
 carbamazepine, 69, 199, 200
 cardiac malformations, 294
 cardiomyopathy, 167, 224, 225,
 236–238
 cardiovascular disease, 204, 205, 216
- caregivers
 checklist of information, 70
 dosages and, 104
 initiating clozapine and, 61
 monitoring role, 72
- CATIE study, 160, 164
 CBC monitoring, point-of-care, 136
 Child–Pugh criteria, 93
 children, 277, 279–285
 adverse effects of clozapine, 284
 plasma clozapine levels, 282
 principles for clozapine use, 281
 randomized, double-blind studies,
 279
- chlorpromazine, 10, 81, 190
 cholinergic rebound, 78, 82
 ileus risk, 74
 Kane study, 12
 liver function and, 269
- cholestasis, 269
 cholinergic rebound
 chlorpromazine, 78, 82
 clozapine, 80
 definition, 79
 diabetes patients, 214
 ileus and, 153
 management of, 81–83
 neuroleptic malignant syndrome,
 250
 severe neutropenia, 134
 symptoms, 80
- ciprofloxacin, 69
 Clinical Global Impression (CGI)
 severity scale, 51, 55, 285
- clonazepam, 199
 clonidine, 177, 183
 clozapine

- adverse effects, 105, 106,
284, 287, 288, 292. *See also*
individual adverse effects
- binding profile, 98–102
- cholinergic rebound, 80
- comparative double-blind trials,
12
- discontinuing. *See* discontinuing
clozapine
- dose reduction. *See* dose
reduction
- ECT and, 200
- FDA approval, 117
- FDA prescribing guidelines, viii
- first synthesis of, 10
- hematologic monitoring. *See*
hematologic monitoring
- impact of delays in commencing,
16
- initiating. *See* initiating clozapine
mania and, 284
- metabolic adverse effects. *See*
metabolic adverse effects
- metabolism and kinetics, 91–98
- mortality and, 18, 21, 204
- pivotal trial, 12
- plasma levels. *See* plasma
clozapine levels
- pregnancy outcome and, 294–295
- prescriber fear, 6
- primary metabolites, 91
- product registration, 11
- real-world effectiveness studies,
16, 17
- slow tapering of, 81
- smoking and, 97
- suicide and, 26
- titration. *See* titration
- underutilization, viii, 1
- underutilization, adolescents, 282
- underutilization, treatment-
resistant schizophrenia, 4, 6
- utilization, strategies for
increasing, 7
- clozapine efficacy, 11, 37
- background, 10–13
- Parkinson's disease psychosis,
33–36
- plasma levels monitoring, 108–
109
- psychogenic polydipsia, 21–24
- suicidality, 25
- treatment-intolerant
schizophrenia, 24
- treatment-resistant mania, 31–33
- treatment-resistant schizophrenia,
13–21
- violence and aggression, 27–31
- clozapine positive symptom
nonresponse, 45–56
- antipsychotic augmentation,
48–49
- ECT and, 50–53
- increasing plasma levels, 47–48
- nonantipsychotic augmentation,
53–55
- patient adherence and, 45–46
- clozapine resource centers, 8
- clozapine-*N*-oxide, 91, 98
- CLOZARIL, 125, 134, 262
- Clozaril Collaborative Study Group,
viii
- colonic transit time (CTT), 140, 142,
148
- complete blood count (CBC), 63, 71
- compression stockings, 166
- congenital malformations, 277, 293,
295
- congestive heart failure, 166
- constipating medications, 75
- constipation, 19, 74, 140, 141–148,
149–155
- criteria, 143–144
- first-line agents for, 146, 148
- opioid-induced, 143, 144
- prevalence and postulated
mechanisms, 142
- PRN medications, 152
- treatment, 144–153
- corpora cavernosa, 247

INDEX

- C-reactive protein (CRP), 65, 225, 230, 231, 233
 creatinine, 233
 CYP
 inducers, 94
 inhibitors, 93, 94
 CYP 1A2, 67, 69, 85
 clozapine metabolism and, 92
 inducers, 95
 infections and, 107
 inhibitors, 95
 metabolic ratio and, 102, 103
 smoking, caffeine and genetic polymorphisms, 94–97
 CYP 2D6, 85, 95
 inhibitors, 95
 CYP 3A4, 95
 CYP P450 inhibitors, 193
 CYP/PGP inducer effects, 93
 CYP polymorphisms, 94, 96
- daily maximum limits, 82
 DARC genotype, 118, 119, 120
 delays in commencing clozapine, 16
 delusions, violence and, 28
 deutetrabenazine, 252
 diabetes mellitus, 204, 207, 213–215
 criteria for, 208
 diagnosis, 208
 gestational, 295, 296
 initiating clozapine, 63
 risk factors, 214
 diabetic ketoacidosis (DKA), 207, 213
 dietary counseling, 205, 206, 217
 diminishing tolerability, 47, 109
 diphenhydramine, 81, 82
 disability-adjusted life year, 1
 discontinuing clozapine, 79–80.
 See also cholinergic rebound
 metabolic effects and, 207
 myocarditis, 231
 orthostasis and, 158
 Parkinson's disease psychosis, 86–87
 priapism, 247
 sedation and, 158, 160
 sialorrhea and, 173
 divalproex, 53, 54, 55, 94, 125.
 See also valproate
 adverse effects, 259, 260
 seizures and, 193, 195, 198, 200
 thrombocytopenia and, 266
 divided doses, plasma levels and, 104
 dizziness, 165
 docusate, 141, 146, 147
 donepezil, 80
 dopamine D₂ antagonism, 99, 250
 occupancy with clozapine, 101
 dopamine D₂ antagonism
 intolerance, 12, 13, 24, 83
 antipsychotic options, 84
 antipsychotic trials, 16
 dose reduction, 107
 constipation and, 152
 sedation and, 161
 dose titration trial, 109, 110
 DRESS, 225, 228, 234, 262
 mortality, 234
 Drooling Severity and Frequency Scale, 172, 177, 178, 179
 drug abuse
 methylphenidate and amphetamines, 163
 modafinil and, 163
 DSM-5, psychosis scoring, 55
 Duffy antigens, 118
 Dutch Clozapine Collaboration Group, 8
 dyslipidemia, 63, 205, 207, 215
- ECG, 64, 65, 105, 167
 cardiomyopathy, 237
 myocarditis, 230, 231, 233
 necessity of, 65
 ECT
 clozapine and, 200
 clozapine nonresponders, 50–53
 EEG, 194
 seizures and, 193
 elimination half-life, 298

- enemas, 152
- enuresis, 242, 243, 244–247, 254
 approaches to treatment, 246
- eosinophilia, 116, 131, 259,
 261–264
 DRESS, 225, 228, 234, 262
 incidence of, 258
 thresholds, 262
 US language on, 262
- eosinophils, 261
 baseline, 63
 reference ranges, 131
 UK reference ranges, 261
- ephedrine, 246
- epilepsy, 195
- erectile dysfunction, 247
- ethnicity. *See also*
 African descent
 diabetes risk factor, 214
 metabolic adverse effects and, 209
 platelet count and, 265
- exercise, 205, 206, 216–217
- extrapyramidal symptoms, 251
- factor Xa inhibitors, 249
- falls, 158, 287
- famotidine, 54
- fatty liver index, 269
- FDA
 clozapine approval, 117
 clozapine prescribing guidelines,
 viii
 inhibitor/inducer definitions, 94
- fever, 62, 224, 225, 226–227
 clozapine-related, case series, 227
 definition, 226
 general principles of approaching,
 228
- filgrastim, 133, 134–136, 267
- first-dose effect, 166
- floppy infant syndrome, 295
- fludrocortisone, 165, 166
- fluvoxamine, 69
- formulations, 72, 91, 93
- Framingham Formula, 64, 65
- Fridericia Formula, 64, 65
- gabapentin, 198
- G-CSF levels, 261, 264
- generalized seizures, 194
- genetic polymorphisms, 94, 96
- gestational diabetes mellitus, 295,
 296
- glucagon-like peptide-1 (GLP-1),
 211
- glutamate neurotransmission, 100
- glycine, 53
- glycine transporters, 100
- glycopyrrolate, 185
 sialorrhea, 173, 178
- goserelin, 248
- granulocytosis, 132
- guanfacine, 183
- Hale classification, 295
- hallucinations, 28, 86
- haloperidol, 49
 aggression and, 31
 Kane study, 12
 response threshold, 85
- heart transplantation, 238
- hematologic guidelines, USA and
 UK, 117
- hematologic monitoring. *See also*
 absolute neutrophil count (ANC)
 UK, 116, 128
 USA, 116, 126, 127
- HemoCue WBC DIFF, 136
- hemoglobin, 267
- hepatic function abnormalities, 260,
 268–271
 general approach to tests, 270
- HF-1854, 10
- high-density lipoprotein (HDL),
 215
- histamine H₁ antagonism, 99
- HLA markers, 124, 125
- hyperosmolar hyperglycemic states
 (HHS), 207
- hypersalivation. *See* sialorrhea
- hypertension, 207, 214
 criteria for, 208
- hypertriglyceridemia, 215

INDEX

- hyponatremia, 21
hypotension, 69
 orthostatic. *See* orthostasis
- ileus
 diagnosing, 153
 mortality, 140, 142, 153
 rechallenging, 154
 risk, 73, 142
 treatment, post-rechallenging, 155
 when to suspect, 154
- iloperidone, 84
- impulsive violence, 28, 29
- incontinence, 242, 243, 244–247, 254
 approaches to treatment, 246
- inducers, 93
 CYP, 94, 95
 strength of, 94, 95
- inflammatory cytokines, 107
- informed consent, 70
- inhibitors, 93
 CYP, 94, 95
 strength of, 94, 95
- initiating clozapine, 61–62, 65–75
 baseline laboratory measures, 63
 baseline vital signs, 62
 baseline work-up, 62, 65
 checklist of information, 70
 formulations, 72
 managing orthostasis, 166
 managing sedation, 161
 monitoring during, 72
 monitoring, inpatient, 72
 monitoring, outpatient, 72
 patient discussions prior to, 70
 QT correction formula, 65
 registration, 66
 tapering concomitant medications, 73–75
 titration, 67–70
- instrumental violence, 28
- insulin resistance, 205, 206, 213
- intellectual disability (ID) patients, 277, 289–293
 adverse effects, 292
 nonpsychotic, 290–291
 psychotic, 291
- interleukin-5 (IL-5), 261
- InterSePT study, 25, 26
- interstitial nephritis, 225, 228, 232
 routine laboratory monitoring, 233
 summary of cases, 232
- intramuscular (IM) formulation, 72, 91
- ipratropium, 173, 178, 179, 181
- irritable bowel syndrome (IBS), 149
- Kane criteria, 13
- Kane study, 12
- Ki nM receptors, 98
- kinetics, clozapine, 91–98
- laboratory error, 105, 297
- lactulose, 146
- lamotrigine, 198, 200
- left ventricular dysfunction, 231
- left ventricular ejection fraction (LVEF), 225, 236, 237
- leukocytosis, 264
 general approach to, 265
 incidence of, 258
- leukopenia, 117
- levetiracetam, 199, 200
- levodopa psychosis, 34
- levodopa-induced dyskinesias (LID), 35
- Lewy bodies, 33
- lifestyle modification, 216–217
- linaclotide, 150, 151
- lithium, 125, 264
 augmentation, 132
 granulocytosis and, 132
- lubiprostone, 149, 150, 151
- magnesium, 147, 148
- magnesium citrate, 152
- magnesium hydroxide, 152

- mania, 80, 253, 284
 - treatment-resistant, 31–33
- medication nonadherence. *See* nonadherence
- memantine, 54
- metabolic adverse effects, 205–219.
 - See also* weight gain
 - discontinuing clozapine, 207
 - monitoring parameters, 208
 - principles of managing on clozapine, 206
- metabolic ratio (MR), 92, 102, 281
 - adolescents and children, 283
 - guidelines for interpreting, 103
 - infections and, 106–108
 - older patients, 286
 - overdose and, 298
- metabolic syndrome, 65, 204, 207
 - components of, 207
 - criteria for, 208
 - prevalence of, 213
- metabolism, clozapine, 91–98
- metformin, 205, 206, 207, 211–212
 - children and adolescents, 281
- methylphenidate, 163
- mineral oil (liquid paraffin), 148
- minocycline, 54
- mirabegron, 245, 246
- mirtazapine, 100
- modafinil, 163
- monitoring, 71
 - inpatient, 71
 - outpatient, 71
- mortality
 - clozapine and, 18–21, 204
 - DRESS, 234
 - ileus, 140, 142, 153
 - postmortem redistribution, 278, 299–301
 - severe neutropenia, 114, 134
 - smoking, 218
 - suicide and, 25
- muscarinic M1/M3 antagonism, 99
- muscarinic M1/M5 agonism, 99
- muscarinic M3 antagonism, 245
- muscarinic antagonism, 142, 175, 176
- muscarinic intrinsic activity, 99, 176
- myocarditis, 65, 168, 195, 225, 228–232
 - essential facts, 231
 - incidence of, 229
 - monitoring for, 71
 - routine laboratory monitoring, 233
 - time to onset, 229
- myoclonic jerking, 297
- neuroleptic malignant syndrome (NMS), 24, 243, 244, 250–251
 - diagnostic criteria, 251
- neutropenia, 11, 195, 200
 - ANC levels, monitoring, 126
 - BEN. *See* benign ethnic neutropenia (BEN)
 - children and adolescents, 280
 - hypothesized mechanism, 125
 - other sources of, 120
 - severe. *See* severe neutropenia
 - terminology, 116
 - time course and risk factors, 117
 - valproate and, 122, 125
- neutrophilia, 258, 264
 - causes of, 264
- nicotine replacement therapy, 219
- NMDA glutamate receptors, 53, 54, 100
- Nocturnal Hypersalivation Rating Scale, 172, 178, 179
- nonadherence, 45–46, 60
 - plasma levels and, 104
 - rates, 16
- nonalcoholic fatty liver disease (NAFLD), 215, 269, 270
- nonantipsychotic augmentation
 - clozapine nonresponders, 53–55
- norclozapine, 68, 91. *See also* metabolic ratio (MR)
 - binding profile, 98–102
 - infections and, 106
 - plasma levels, 102
 - sialorrhea and, 175

INDEX

- obesity, criteria for, 208
 obsessive compulsive disorder, 243,
 244, 252
 approach to new onset, 253
 olanzapine, 84
 aggression and, 31
 cholinergic rebound, 81
 double-blind trials, 13
 Parkinson's disease psychosis,
 35, 36
 response threshold, 85
 suicide and, 26
 tapering, 74
 older patients, 277, 285–289
 adverse effects of clozapine, 287,
 288
 omeprazole, 69, 72, 92, 93, 95, 102,
 121, 161, 165
 opioids, constipation and, 143, 144
 oral formulations, 72, 91
 oral suspension, 72
 orally disintegrating tablet (ODT), 72
 organized violence, 28
 orthostasis, 62, 145, 164–166, 169
 clozapine initiation, 75
 definition, 164
 falls and, 158
 seizures and, 194
 tachycardia and, 168
 vital signs, 72
 overactive bladder, 246
 overdose, 277, 278, 297–299
 paralytic ileus, 140
 Parkinson's disease (PD), 33
 medications, 145
 Parkinson's disease psychosis
 (PDP), 33–36
 consensus definition, 33
 discontinuing clozapine, 86–87
 titration levels, 70
 partial seizures, 194
 patient discussions, 70
 checklist, 70
 patient nonadherence. *See*
 nonadherence
 PEG-3350, 141, 146, 148
 perphenazine, 20
 Petrides' study, 51
 PGP, 92
 CYP/PGP inducer effects, 93
 phenytoin, 69, 122, 199, 200
 physical activity vital sign (PAVS),
 210, 216
 pimavanserin, 70, 83
 5HT_{2A} affinity, 100
 D₂ antagonism intolerance, 84
 Parkinson's disease psychosis,
 36, 86
 pirenzepine, 176
 pivotal clozapine trial, 12
 plasma antipsychotic levels, 45
 plasma clozapine levels, 46, 91,
 102–109
 adolescents and children, 282
 clozapine nonresponders and,
 47–48
 conversion formulas, 108
 decreasing, for constipation, 152
 early in treatment, 69
 infections and, 106–108
 markedly below expected, 104
 markedly higher than expected,
 106–108
 monitoring efficacy, 108–109
 nonresponders, 47
 older patients, 286, 288
 overdose and, 297
 postmortem redistribution, 300
 principles for obtaining, 104
 threshold, 47
 units used, 90, 108
 upper limits, 109, 110
 platelet count, 116, 131, 265–267
 platelets, UK reference ranges, 131,
 261
 plecanatide, 150, 151
 point of futility, 47, 109
 point-of-care CBC monitoring, 136
 Porirua constipation protocol, 148
 Positive and Negative Syndrome
 Scale (PANSS), 48

- postmortem redistribution, 278, 299–301
- predatory violence, 28
- pregnancy, 277, 278, 293–295
 - anticonvulsants and, 200
 - clozapine and, 294–295
 - thrombocytopenia and, 266
- prescriber fear, 6
- priapism, 243, 247–248, 254
- primary metabolites, clozapine, 91
- primary polydipsia, 21, 23
- propensity scores, 293
- propranolol, 168, 281
- prucalopride, 141, 151, 154
- psychogenic polydipsia, 21–24
- psychotic violence, 28
- psychotropics
 - constipation and, 145
 - tapering, 74
- PSYCLOPS trial, 34
- psyllium, 148
- PubMed, clozapine publications in, 1
- pulmonary embolism, 248, 250
- QHS dosing, 97
- QT correction formula, 65
- QT monitoring, 65
- QT prolongation, 167
- quetiapine, 17
 - adverse effects, 24
 - D₂ antagonism intolerance, 84
 - mortality rates, 20
 - Parkinson's disease psychosis, 35, 36, 87
 - tapering, 74
- rechallenging
 - eosinophilia, 262
 - ileus, 154
 - interstitial nephritis, 233
 - myocarditis, 231
 - priapism, 247
 - severe neutropenia, 134
- RegiSCAR, 234
- registration, 66
- repetitive transcranial magnetic stimulation (rTMS), 53
- response threshold, 46, 47, 69, 109
 - haloperidol, 85
 - olanzapine, 85
- rhabdomyolysis, 297
- ribavirin, 135
- risperidone, 83, 100, 294
- Rome IV diagnostic criteria, 143
- salivary glands, 174
- schizoaffective disorder, bipolar type, 32
- schizophrenia
 - antipsychotic mortality studies, 20
 - childhood onset, 279
 - costs in the US, 2
 - disease burden of, 1
 - enuresis and, 244
 - prevalence, 1, 3
 - prevalence, age-standardized, 3
 - real-world effectiveness studies, 17
 - treatment-intolerant, 24
 - treatment-resistant. *See* treatment-resistant schizophrenia
 - violence risk estimates, 27
- schizophrenia spectrum disorders
 - antipsychotic options, 84, 85
 - clozapine initiation, 60
 - mortality and, 25
 - plasma levels, 69
 - suicidality and, 25
- secondary polydipsia, 21
- secretagogues, 141, 149–151, 154
- sedation, 159, 160–164, 169
 - effects, 73
 - falls and, 158
- seizures, 48, 191–200, 201
 - clozapine and, 192, 193, 194
 - dose-dependency and, 191, 193, 196–197
 - neonatal, 295
 - treatment of, 197–200
 - types and frequencies, 194

INDEX

- sennosides, 146
 serositis, 225, 228, 235
 serotonergic motility agents,
 149–151
 serotonin 5HT_{2a} inverse agonism, 99
 serotonin 5HT_{2a} occupancy with
 clozapine, 101
 serotonin 5HT_{2a} receptors, 34, 86
 sertraline, 253
 serum creatinine, 233
 serum osmolality, 21, 22
 severe cutaneous adverse reactions
 (SCARs), 234
 severe neutropenia, 115, 116
 breastfeeding and, 296
 estimates for clozapine, 117
 fever and, 228
 mortality from, 114, 134
 other medications and, 121
 rechallenging, 134
 time course of, 123–125
 sialorrhea, 19, 173–186
 clozapine-induced, 175–177
 prevalence, 172
 treatment principles, 177–185
 single nucleotide polymorphisms
 (SNPs), 96
 smoking, 218–219
 anticholinergics and, 74, 82
 clozapine and, 97
 CYP 1A2 activity and, 96
 inhibitor/inducer effects and, 94
 monitoring, 210
 mortality rates, 218
 titration and, 67, 68, 69
 SNARE proteins, 180, 182
 sodium benzoate, 54
 SSRIs, 252, 253
 Stevens–Johnson Syndrome, 200,
 234
 stimulants, 141
 stool form nomenclature, 143–144,
 145
 STRIDE protocol, 217
 stuttering, 191, 197
 substance use, violence and, 27
 suicidality, 25, 278
 InterSePT study, 25, 26
 overdose and, 298
 type 1 and type 2 events, 26
 sulpiride, 184
 systemic inflammation, 216
 tachycardia, 62, 65, 159, 166–167,
 169, 298
 decision algorithm, 167
 definition, 166
 tardive dyskinesia, 24, 194, 197,
 243, 244, 252
 thrombin inhibitors, 249
 thrombocytopenia, 122, 131, 259,
 265–267
 general approach to, 265
 incidence of, 258, 266
 thrombocytosis, 259, 265–267
 general approach to, 265
 incidence of, 258
 timing, plasma levels and, 104
 titration, 67–70
 children and adolescents, 277,
 281, 284
 clozapine, 47
 dose titration trial, 109, 110
 older patients, 285, 287
 principles of, 67, 110
 rapid, 68, 69
 slower, 68
 tonic-clonic seizures, 194
 topiramate, 53, 54, 55
 transabdominal ultrasound, 245, 246
 traveling, difficulties in, 61
 treatment-intolerant schizophrenia,
 24
 treatment-resistant mania, 31–33
 treatment-resistant schizophrenia
 adolescents, 279, 280, 282
 children, 279
 clozapine efficacy, 13–21

- clozapine underutilization, 4, 6
- consensus criteria for an adequate trial, 15
- costs of, 2
- ECT and, 200
- Kane criteria, 13
- olanzapine trials, 13
- pivotal clozapine trial, 12
- plasma level ranges, 109
- prevalence, 2
- suicidality and, 25
- tricyclic antidepressants, 74, 144
- trihexyphenidyl, 82
- troponin, 65
- troponin I/T level, 225, 230, 231, 233
- UGT1A 4, 94
- UK
 - clozapine prescriptions, 6
 - clozapine registration, 66
 - eosinophil/platelet reference ranges, 131, 261
 - hematologic monitoring, 116, 128
- UK Diabetes Prevention Program trial, 213
- urinalysis, 233
- urine osmolality, 21, 23
- urodynamic testing, 246, 247
- USA. *See also* FDA
 - clozapine prescribing guidelines, 94
 - clozapine prescriptions, 5
 - clozapine registration, 66
 - costs of schizophrenia, 2
 - eosinophilia, language on, 262
 - guidelines on dose adjustment, 95
 - hematologic guidelines, 117
 - hematologic monitoring, 116, 126, 127
 - valbenazine, 252
 - valproate, 54, 198, 200. *See also* divalproex
 - neutropenia risk, 122, 125
 - valproic acid, 94, 195
 - varenicline, 218
 - venous thromboembolism, 243, 248–250, 254
 - risk assessment tool, 249
 - violence, 27–31, 163
 - risk estimates in schizophrenia, 27
 - viral infections, 103, 105, 106–108
 - clozapine management during, 107
 - minimization of risk, 135
 - visual hallucinations, 86
 - VMAT2 inhibitors, 24, 252
 - waist circumference, 65, 208, 209
 - warfarin, 249
 - weight gain, 63, 65, 205
 - antipsychotic-related, 210, 211
 - children and adolescents, 281
 - nonmodifiable risk factors, 206
 - white blood cells (WBCs), 7, 116
 - leukocytosis, 264
 - low, and treatment interruption, 131–134
 - racial variations, 118
 - UK hematologic monitoring, 128
 - WHO Global Burden of Disease Study 2016, 1
 - withdrawal symptoms. *See* cholinergic rebound
 - Young Mania Rating Scale (YMRS)
 - score, 32, 80
 - Young Mania Rating Scale (YMRS)
 - score, 33, 79
 - Zollinger–Ellison syndrome, 54